In a landmark decision, the National Institute for Health and Care Excellence (NICE) has recommended Lynparza (olaparib) for use within the NHS in England and Wales. This approval marks a significant milestone in the treatment of HER2-negative, locally advanced, or metastatic breast cancer in adults with germline BRCA1 or BRCA2 mutations, following chemotherapy.
Breast cancer remains one of the most prevalent cancers worldwide, and germline BRCA1 and BRCA2 mutations account for 5% to 10% of all cases. For these patients, targeted therapies like olaparib represent some hope. Professor Andrew Tutt, Director of the Toby Robins Breast Cancer Now Research Centre, emphasised the importance of this approval, stating: “Locally advanced or metastatic HER2-negative breast cancer remains a devastating diagnosis. For those with this form of breast cancer and inherited BRCA mutations, the OlympiAD phase 3 trial demonstrated how olaparib can significantly delay cancer progression or death compared to standard chemotherapies.”
A Precision Approach to Cancer Treatment
Olaparib is a PARP inhibitor and precision medicine designed to disrupt the DNA repair process in cancer cells. This targeted mechanism helps selectively kill tumour cells while sparing healthy ones, aligning with the growing focus on personalised medicine. The OlympiAD phase 3 trial – pivotal to NICE’s decision – showed that olaparib reduced the risk of disease progression or death by 42% compared to standard chemotherapy, with a consistent safety profile.
Tom Keith-Roach, President of AstraZeneca UK, noted: “We are delighted that NICE has recommended olaparib. This decision is AstraZeneca’s 26th cancer medicine recommendation from NICE and the SMC since 2021.”
Supporting Innovation Through Rigorous Regulation
The approval of olaparib highlights the critical balance between innovation and stringent regulatory oversight. While the development of groundbreaking drugs continues to push the boundaries of what’s possible in oncology, maintaining global compliance ensures that these therapies are both safe and effective. Additionally, the off-licence use of drugs is increasingly recognised as a valuable option for addressing unmet medical needs. However, such applications must meet the highest regulatory standards to protect patient safety and uphold therapeutic efficacy.
The Role of Genetic Testing
The importance of genetic testing cannot be overstated in the era of precision medicine. BRCA mutation testing – available and reimbursed by the NHS via the National Genomic Test Directory – is essential to identify patients who will benefit most from targeted therapies like olaparib. This ensures that the right treatment reaches the right patient at the right time, maximising outcomes and resource efficiency.
A Collaborative Path Forward
NICE’s recommendation of olaparib is a testament to the collaborative efforts of researchers, pharmaceutical companies, and regulatory bodies. By advancing precision medicine and investing in genetic testing, the healthcare community continues to redefine the standard of cancer care, offering hope to patients and their families. As we celebrate this milestone, the commitment to developing innovative treatments and exploring their potential applications remains steadfast. With a patient-first approach, the future of oncology looks brighter than ever.
Back to News + Insights